From the Journals

Breast cancer care delayed when patients have high deductibles


 

FROM JOURNAL OF CLINICAL ONCOLOGY


The investigators conducted a controlled pre-post study to measure the occurrence of outcomes both before and after women were switched from a low-deductible health plan, defined as a maximum annual deductible of $500 or less, to a high-deductible plan, defined as an annual deductible of $1,000 or more.

The study population comprised 273,499 women aged 25-64 years who had no evidence of breast cancer before they were included in the study. The women had all been enrolled in a low-deductible plan for at least 1 year, and were then switched by employer mandate to a high-deductible plan and followed for up to 4 additional years.

Controls included 2.4 million women matched by time of inclusion whose employers continued to offer only low-deductible health plans.

Although at baseline there were no differences between the study sample and the controls in time to first diagnostic breast imaging, breast biopsy, diagnosis of early stage breast cancer, or initiation of breast cancer chemotherapy, at follow-up the women who had been switched to the high-deductible plans had significant delays in all categories.

Recommended Reading

Shaping practice: Z1071 continues to redefine axillary management
MDedge Internal Medicine
VIDEO: Weight loss cut risk of breast cancer
MDedge Internal Medicine
Extra years of adjuvant bisphosphonate not needed in early breast cancer
MDedge Internal Medicine
Postmenopausal women who shed pounds see lower breast cancer risk
MDedge Internal Medicine
POSH study: BRCA mutations did not influence survival in young onset breast cancer
MDedge Internal Medicine
New multi-analyte blood test shows promise in screening for several common solid tumors
MDedge Internal Medicine
STUDY: More mammograms after cost-sharing elimination
MDedge Internal Medicine
AHA: Heart health helps optimize breast cancer outcomes
MDedge Internal Medicine
Breast cancer deaths projected for 2018
MDedge Internal Medicine
FDA authorizes first direct-to-consumer BRCA1/2 test
MDedge Internal Medicine